Ketamine’s Schedule III classification under the federal Controlled Substances Act means the government recognizes it has a legitimate medical use but treats it as a controlled drug with moderate potential for dependence. In practical terms, that classification is why you need a prescription from a DEA-registered practitioner to receive it, why clinics and pharmacies that handle it face detailed storage and record-keeping rules, and why possessing it without authorization is a federal crime. The DEA placed ketamine in Schedule III by a Final Rule published July 13, 1999, effective August 12, 1999, after reports of recreational abuse accumulated through the late 1990s.1GovInfo. Schedules of Controlled Substances – Placement of Ketamine into Schedule III Before that date, ketamine could be obtained without any of the controls that now apply.
What Schedule III Means
The Controlled Substances Act sorts drugs into five schedules based on abuse potential, accepted medical use, and dependence risk. Schedule III drugs have a lower abuse potential than those in Schedules I and II, a currently accepted medical use, and a risk of moderate physical or high psychological dependence.2Office of the Law Revision Counsel. 21 USC 812 – Schedules of Controlled Substances Ketamine is listed as a depressant at 21 CFR 1308.13(c)(7), and the listing covers its salts, isomers, and salts of isomers.3eCFR. 21 CFR 1308.13 – Schedule III That broad language sweeps in esketamine, the S-enantiomer marketed as Spravato, which shares the Schedule III designation.4FDA. Spravato Prescribing Information
Prescription Rules for Patients and Prescribers
A Schedule III prescription can be written, oral, or electronic, but it must come from a practitioner registered with the DEA. Two limits control how long a prescription remains usable: it expires six months from the date it was issued, and it can be refilled no more than five times within that window.5GovInfo. 21 USC 829 – Prescriptions Whichever limit hits first ends the prescription, and the patient needs a new one to continue.6eCFR. 21 CFR 1306.22 – Refilling of Prescriptions
Electronic prescribing of ketamine is allowed, but the prescriber must complete a two-factor authentication step that legally counts as signing the prescription before the software will transmit it.7eCFR. 21 CFR Part 1311 – Requirements for Electronic Orders and Prescriptions
Telehealth Prescriptions
The Ryan Haight Act normally requires an in-person evaluation before a practitioner can prescribe a controlled substance online. That requirement has been suspended repeatedly since the COVID-19 public health emergency. The most recent DEA extension allows registered practitioners to prescribe Schedule II through V controlled substances, including ketamine, through audio-video telehealth encounters without a prior in-person visit through December 31, 2026.8DEA. DEA Extends Telemedicine Flexibilities to Ensure Continued Access to Care The prescription still has to be issued for a legitimate medical purpose and comply with all other federal and state rules.
Rules for Clinics, Pharmacies, and Veterinary Offices
Anyone who handles ketamine professionally takes on a substantial compliance burden that reaches from receipt of the drug through its disposal.
Storage
Practitioners must store ketamine in a securely locked, substantially constructed cabinet. Pharmacies and institutional practitioners have a second option: dispersing controlled substances through their non-controlled stock in a way that makes theft difficult.9eCFR. 21 CFR 1301.75 – Physical Security Controls for Practitioners Small clinics and veterinary offices generally use the cabinet approach.
Records and Inventory
Every inventory, dispensing, and prescription record involving ketamine must be kept for at least two years and must be readily retrievable. Paper prescriptions are typically marked with a red letter “C” at least one inch high, or handled through a computer system that can pull them by prescriber, patient, drug, and date.10eCFR. 21 CFR 1304.04 – Maintenance of Records and Inventories Registrants must take an initial inventory when they begin dispensing and repeat it at least every two years. For opened containers of Schedule III drugs, an estimated count is acceptable unless the container holds more than 1,000 tablets or capsules.11eCFR. 21 CFR 1304.11 – Inventory Requirements
Theft and Loss Reporting
A registrant who discovers a theft or significant loss of ketamine must notify the DEA’s local Field Division Office in writing within one business day and file a completed DEA Form 106 within 45 days.12eCFR. 21 CFR 1301.76 – Other Security Controls for Practitioners Whether a loss is “significant” turns on the amount missing relative to typical inventory, who had access, and whether losses form a pattern.
Veterinary clinics operate under the same rules. Ketamine is one of the most widely used anesthetics in veterinary medicine, and the Schedule III classification applies regardless of whether the intended patient is human or animal.13eCFR. 21 CFR Part 530 – Extralabel Drug Use in Animals
Spravato Is Schedule III but Not Treated Like Off-Label Ketamine
Esketamine, sold as Spravato and FDA-approved for treatment-resistant depression, sits in Schedule III alongside racemic ketamine, but a Risk Evaluation and Mitigation Strategy (REMS) imposed as a condition of approval makes its handling far more restrictive. Patients receive Spravato only in a certified healthcare setting and must be monitored for at least two hours after each dose for sedation, dissociation, vital signs, and respiratory depression.14FDA. Spravato Supplement Approval Letter Patients cannot take it home. Pharmacies dispensing Spravato must be enrolled in the REMS, and product sent for a named patient must be administered within 14 days.15FDA. Spravato REMS Program Requirements
Off-label ketamine infusions for depression operate under an entirely different model. A physician with a DEA registration can prescribe ketamine for any condition they consider medically appropriate, and none of the REMS safeguards apply. Some clinics prescribe ketamine lozenges for at-home use.
Federal Penalties
Simple Possession Without a Prescription
Possessing ketamine without a valid prescription is a federal crime at any amount. Penalties escalate with prior drug convictions under any federal or state law:
- First offense: up to one year in prison and a minimum fine of $1,000.
- One prior drug conviction: 15 days to two years in prison and a minimum fine of $2,500.
- Two or more prior drug convictions: 90 days to three years in prison and a minimum fine of $5,000.16GovInfo. 21 USC 844 – Penalties for Simple Possession
Distribution and Manufacturing
Illegally distributing or manufacturing a Schedule III substance carries a maximum of 10 years in prison for a first offense, with fines up to $500,000 for an individual and $2.5 million for an organization. If someone dies or suffers serious bodily injury, the maximum rises to 15 years. A second offense after a prior felony drug conviction doubles those numbers: up to 20 years in prison, 30 years if death or serious injury results, and fines up to $1 million for an individual and $5 million for an organization.17Office of the Law Revision Counsel. 21 USC 841 – Prohibited Acts A
Civil Penalties for Registrants
DEA registrants who fail to keep required records, run inventories, or otherwise comply with the regulations face civil penalties of up to $19,246 per violation as of mid-2025. That amount adjusts for inflation periodically and stacks quickly when a single audit turns up multiple failures.18eCFR. 28 CFR Part 85 – Civil Monetary Penalties Inflation Adjustment
State Rules Can Be Stricter
Federal scheduling sets a floor. States can classify ketamine more strictly than the federal government, add prescribing restrictions, or require additional reporting, and when federal and state rules conflict, the more restrictive rule controls.
All 50 states operate prescription drug monitoring programs (PDMPs), electronic databases that track dispensed controlled substance prescriptions. Federal grant support under 42 U.S.C. § 280g-3 requires participating states to have enabling legislation and penalties for unauthorized access.19Office of the Law Revision Counsel. 42 USC 280g-3 – Prescription Drug Monitoring Program Reporting timelines, mandatory query rules for prescribers, and interstate data sharing vary by state, so the specific obligations depend on where you practice or fill prescriptions.
Ketamine Analogs Are Not Automatically Covered
Schedule III covers ketamine and its salts, isomers, and salts of isomers. It does not cover every ketamine-like compound. 2-fluorodeschloroketamine (2-FDCK), a related dissociative appearing in seized drug samples, is not currently in any schedule. In January 2026, the DEA published a notice of intent to place 2-FDCK temporarily in Schedule I, which if finalized would make it illegal to manufacture, distribute, or possess and would carry Schedule I penalties for two years while the DEA works through permanent scheduling.20Federal Register. Schedules of Controlled Substances – Temporary Placement of 2-Fluorodeschloroketamine in Schedule I The proposed Schedule I placement for 2-FDCK is stricter than the Schedule III status of ketamine itself, reflecting the absence of any approved medical use for the analog.